This may also include the use of immun osuppressive treatments such as glucocorticoids and replacement hormones if indicated. Other supportive care with blood components, antibiotics, analgesics, general medical therapy, etc., will be delivered as required. Any patients taking antibiotics for any reason must complete that c ourse of therapy and be free of evidence of further infection before receiving any dose of vaccine. Symptomatic anemia should be treated with appropriate red blood cell or erythropoietin support. Other investigational therapies will not be allowed while a subject participates in this study. 5 BIOSPECIMEN COLLECTI ON 5.1 CORRELATIVE STUDIES FOR RESEARCH /PHARMACOKINETIC STUDIES 5.1.1 Parameters of Immune A ctivation 5.1.1.1 Blood samples to be collected: Correlative / Immunology blood: 6 (10mL) green top sodium heparin tubes for PBMC; 2 (8mL) SST tubes for serum samples, 2 (10mL) green top sodium heparin tubes for circulating tumor cell assay . 5.1.1.2 Immunologic /correlative testing will include : • Specific T -cell responses , evaluated using flow cytometry intracellular staining (ICS) of CD4 and CD8 T lymphocytes for cytokines including IFN-γ, tumor necrosis factor, and IL-2. Additional markers of specific T-cell activation may be included based on evolving results with this assay. • CD3, CD4, CD8, and CD19 subsets, NK markers, and CD4:CD8 rat io (baseline, about day 29, and about day 85). • Analysis for cytokines (IFN- γ, IL -10, IL -12, IL -2, IL -4, TGF-ß, etc.), chemokines, antibodies (including yeast and brachyury ), TAAs and/or other markers. • If sufficient samples are available pre- and post- vaccination , PBMCs will be evaluated as follows: a. IFN-γ ELISPOT assays for b rachyury -specific T lymphocytes using a brachyury- specific peptide in selected HLA -A2 peptides. b. A proliferation assay using brachyury protein in selected patients. c. Phenotypic and func tional analysis of immune cell subsets (NK cells and Tregs ). d. For use in a circulating tumor cell analysis in collaboration with Epic Sciences, Inc. ( 10975 N.